In a report released today, Mark Massaro from Canaccord Genuity maintained a Sell rating on Meridian Bioscience (VIVO), with a price target of $8.00. The company’s shares closed last Monday at $8.76, close to its 52-week low of $7.63.
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 22.5% and a 64.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Orasure Technologies, and Chembio Diagnostics.
Currently, the analyst consensus on Meridian Bioscience is a Moderate Sell with an average price target of $8.50.
See today’s analyst top recommended stocks >>
Based on Meridian Bioscience’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $4.1 million. In comparison, last year the company had a net profit of $5.43 million.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VIVO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the Diagnostics and Life Science segment.
